DSIP has been studied in people, so describing its evidence as entirely animal-based would be inaccurate. The more important question is whether the human findings reliably establish a clinically useful treatment for insomnia. The available record does not support a confident general promise.
Positive and less positive results belong together
A 1987 study abstract reported improved sleep and daytime function in fourteen people. However, the FDA's 2026 assessment identified important design limitations, including the lack of a parallel placebo arm despite the publication's description of placebo control. Placebo was used on baseline and post-treatment nights; the FDA treated the comparative evidence as externally controlled.
A separate 1992 double-blind study enrolled sixteen people and found weak changes, some potentially explained by changes in the placebo group. Its authors did not consider the short-term results likely to provide major therapeutic benefit.
Selecting only the encouraging abstract would omit a material part of the evidence. Calling every study negative would also be an oversimplification.
Statistical signals are not a complete clinical answer
A small change in one measurement must be considered alongside subjective sleep quality, daytime function, adverse events and the comparison group. A study can suggest biological activity without establishing an effective treatment plan.
Small studies also leave uncertainty about uncommon harms, longer exposure and which patients might benefit. Their formulations and administration routes cannot automatically be transferred to a product purchased today.
How to read an insomnia claim
Ask whether the cited research studied diagnosed insomnia, healthy volunteers or another condition. Then identify the outcome, comparator, follow-up period and exact intervention. A trial title containing sleep does not answer all of those questions.
The FDA briefing is a dated scientific and compounding assessment, not itself a final approval decision. Its analysis nevertheless explains why the historical literature should not be converted into a routine home-use regimen.
For persistent sleep difficulty, a clinician can assess the underlying problem and discuss treatments with evidence for that diagnosis. A mixed historical research record is not a reason to abandon established care or assume that a peptide has solved the uncertainty.